PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

被引：12

作者：

Jia, Xiaoming ^{[1
]}

Al Rifai, Mahmoud ^{[1
]}

Saeed, Anum ^{[2
]}

Ballantyne, Christie M. ^{[1
]}

Virani, Salim S. ^{[1
,3
]}

机构：

[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA

[2] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA

[3] Michael E DeBakey VA Med Ctr, Dept Med, Houston, TX 77030 USA

来源：

VASCULAR HEALTH AND RISK MANAGEMENT | 2022年 / 18卷

关键词：

PCSK9; inhibitor; CVD prevention; lipids; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; PERIPHERAL ARTERY-DISEASE; 9; MONOCLONAL-ANTIBODY; COST-EFFECTIVENESS; DOUBLE-BLIND; ALIROCUMAB TREATMENT; LOWERS CHOLESTEROL; LDL CHOLESTEROL; REDUCING LIPIDS; AMG; 145;

D O I：

10.2147/VHRM.S275739

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

引用

页码：555 / 566

页数：12

共 50 条

[1] PCSK9 inhibitors
Gencer, Baris
Lambert, Gilles
Mach, Francois
SWISS MEDICAL WEEKLY, 2015, 145
[2] PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, Rose Q.
Vogel, Robert A.
Schwartz, Gregory G.
CURRENT CARDIOLOGY REPORTS, 2013, 15 (03)
[3] Introduction of PCSK9 inhibitors. New perspectives in treatment and practical implementation
Klose, G.
HERZ, 2016, 41 (04) : 307 - 312
[4] PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
Handelsman, Yehuda
Lepor, Norman E.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (13):
[5] Practical guide for the use of PCSK9 inhibitors in Portugal
Fontes-Carvalho, Ricardo
Silva, Pedro Marques
Rodrigues, Elisabete
Araujo, Francisco
Gavina, Cristina
Ferreira, Jorge
Morais, Joao
REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (06) : 391 - 405
[6] PCSK9 inhibitors for treating hypercholesterolemia
Pasta, Andrea
Cremonini, Anna Laura
Pisciotta, Livia
Buscaglia, Angelo
Porto, Italo
Barra, Fabio
Ferrero, Simone
Brunelli, Claudio
Rosa, Gian Marco
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 353 - 363
[7] PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
Tavori, Hagai
Giunzioni, Ilaria
Fazio, Sergio
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 126 - 132
[8] PCSK9 inhibitors and cardiovascular outcomes
Steffens, Daniel
Bramlage, Peter
Scheeff, Celine
Kasner, Mario
Hassanein, Adel
Friebel, Julian
Rauch-Kroehnert, Ursula
EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
[9] Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Shah, Parth
CURRENT CARDIOLOGY REPORTS, 2018, 20 (07)
[10] PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, Stephen J.
KARDIOLOGIA POLSKA, 2023, 81 (02) : 115 - 122

← 1 2 3 4 5 →